In one paragraphArticle in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from itWhat it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
13 authors.
Martijn VochtelooDepartment of Genetics, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.ORCID 0000-0002-6385-0550 Anoek KooijmansDepartment of Genetics, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.ORCID 0009-0005-4271-3353 Joost BakkerDepartment of Genetics, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
Roy OelenDepartment of Genetics, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.ORCID 0000-0002-5026-6531 Jelmer NiewoldDepartment of Genetics, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.ORCID 0009-0008-5840-1399 Dan KaptijnDepartment of Genetics, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.ORCID 0009-0008-7529-2040 Marc Jan BonderDepartment of Genetics, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.ORCID 0000-0002-8431-3180 Monique van der WijstDepartment of Genetics, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.ORCID 0000-0003-1520-3970 Julien BryoisRoche Pharma Research and Early Development, Neuroscience and Rare Diseases, Roche Innovation Center, CH-4070, Basel, Switzerland.ORCID 0000-0002-4747-2166 Lude FrankeDepartment of Genetics, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.ORCID 0000-0002-5159-8802 Harm-Jan WestraDepartment of Genetics, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.ORCID 0000-0001-7038-567X Funding
SUPPLEMENT TO RUSH ALZHEIMERS DISEASE CENTER COREP30AG010161 · NIA · RUSH UNIVERSITY MEDICAL CENTER · PI LEURGANS, SUE E. · 1991 to 2020
$49.1MEPIDEMIOLOGY OF NEURAL RESERVE AND NEUROBIOLOGY IN AGINGR01AG017917 · NIA · RUSH UNIVERSITY MEDICAL CENTER · PI BENNETT, DAVID ALAN · 2001 to 2023
$43.3MRush Alzheimer's Disease Research CenterP30AG072975 · NIA · RUSH UNIVERSITY MEDICAL CENTER · PI Lisa L Barnes, Julie A. Schneider · 2021 to 2026
$24.7MRISK FACTORS, PATHOLOGY, AND CLINICAL EXPRESSIONS OF ADR01AG015819 · NIA · RUSH UNIVERSITY MEDICAL CENTER · PI BENNETT, DAVID ALAN · 1998 to 2024
$21.4MMulti-omic network-directed proteoform discovery, dissection and functional validation to prioritize novel AD therapeutic targetsU01AG061356 · NIA · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI BENNETT, DAVID ALAN, DE JAGER, PHILIP L · 2018 to 2022
$13.7MPathway discovery, validation and compound identification for Alzheimer's disease - SupplementU01AG046152 · NIA · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI BENNETT, DAVID ALAN, DE JAGER, PHILIP L · 2013 to 2017
$13.6MIdentification of TDP-43 Modifiers Through Single-Cell Transcriptional and Epigenomic Dissection of ALS and FTLD-MNDR01NS127187 · NINDS · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI BELZIL, VERONIQUE, DONNELLY, CHRISTOPHER JAMES · 2021 to 2025
$9.1MAlzheimer variants: Propagation of shared functional changes across cellular networksU01AG072572 · NIA · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI DE JAGER, PHILIP L, ST GEORGE-HYSLOP, PETER HENRY · 2021 to 2025
$8.5MEpigenomic, transcriptional and cellular dissection of Alzheimer's variantsR01AG058002 · NIA · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI HYMAN, BRADLEY T., JAENISCH, RUDOLF · 2017 to 2021
$7.9M Functional Genomics of Human Brain DevelopmentP50MH106934 · NIMH · YALE UNIVERSITY · PI SESTAN, NENAD · 2014 to 2019
$7.9MCis-Regulatory Epigenome Mappings in SchizophreniaU01MH103392 · NIMH · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI AKBARIAN, SCHAHRAM, SKLAR, PAMELA · 2014 to 2017
$7.6MMolecular Profiling of SchizophreniaR01MH110921 · NIMH · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI CHESS, ANDREW J, ROUSSOS, PANAGIOTIS · 2016 to 2020
$6.9MNHGRI NIH HHS R01 HG008155NIA NIH HHS P30 AG010161NIA NIH HHS P30 AG072975NIA NIH HHS R01 AG015819NIA NIH HHS R01 AG017917NIA NIH HHS R01 AG058002NIA NIH HHS R01 AG062335NIA NIH HHS R01 AG066831NIA NIH HHS R01 AG074003NIA NIH HHS RF1 AG054012NIA NIH HHS RF1 AG054321NIA NIH HHS RF1 AG057473NIA NIH HHS RF1 AG062377NIA NIH HHS U01 AG046152NIA NIH HHS U01 AG061356NIA NIH HHS U01 AG072572NIDA NIH HHS U01 DA048279NIGMS NIH HHS T32 GM087237NIMH NIH HHS P50 MH106934NIMH NIH HHS R01 MH094714NIMH NIH HHS R01 MH105472NIMH NIH HHS R01 MH105898NIMH NIH HHS R01 MH109677NIMH NIH HHS R01 MH109715NIMH NIH HHS R01 MH110905NIMH NIH HHS R01 MH110920NIMH NIH HHS R01 MH110921NIMH NIH HHS R01 MH110926NIMH NIH HHS R01 MH110927NIMH NIH HHS R01 MH110928NIMH NIH HHS R01 MH111721NIMH NIH HHS R01 MH117291NIMH NIH HHS R01 MH117292NIMH NIH HHS R01 MH117293NIMH NIH HHS R01 MH125516NIMH NIH HHS R21 MH102791NIMH NIH HHS R21 MH103877NIMH NIH HHS R21 MH105853NIMH NIH HHS R21 MH105881NIMH NIH HHS R21 MH109956NIMH NIH HHS R56 MH114899NIMH NIH HHS R56 MH114901NIMH NIH HHS R56 MH114911NIMH NIH HHS U01 MH103339NIMH NIH HHS U01 MH103340NIMH NIH HHS U01 MH103346NIMH NIH HHS U01 MH103365NIMH NIH HHS U01 MH103392NIMH NIH HHS U01 MH116438NIMH NIH HHS U01 MH116441NIMH NIH HHS U01 MH116442NIMH NIH HHS U01 MH116487NIMH NIH HHS U01 MH116488NIMH NIH HHS U01 MH116489NIMH NIH HHS U01 MH116492NIMH NIH HHS U01 MH119509NIMH NIH HHS U01 MH122509NIMH NIH HHS U01 MH122590NIMH NIH HHS U01 MH122591NIMH NIH HHS U01 MH122592NIMH NIH HHS U01 MH122678NIMH NIH HHS U01 MH122681NIMH NIH HHS U01 MH122849NINDS NIH HHS R01 NS127187NINDS NIH HHS U01 NS110453NINDS NIH HHS UG3 NS115064NINDS NIH HHS UH3 NS115064
6 · The paper itselfAbstract
Identifying causal mechanisms from genome-wide association studies (GWAS) requires an understanding of how disease-associated genetic variants influence gene expression in specific cell types. Here, we present scMetaBrain, a large-scale single-nucleus RNA-sequencing (snRNA-seq) resource derived using 1,260 samples from 785 individuals spanning 10 brain datasets. By analyzing 3.9 million transcriptomes, we identified 19,371 unique expression quantitative trait locus (eQTL) genes (eGenes) at a major cell type level, with the largest number of eQTLs observed in excitatory neurons. Notably, 31% of the eQTLs detected were highly cell-type-specific, with most restricted to excitatory neurons (69%). We compared the eQTLs with bulk RNA-seq datasets across different tissues and with a newly generated single nucleus dataset of 123 donors from peripheral blood mononuclear cells. We observed that differences in eQTL effect sizes between brain cell types are often as large as comparing eQTLs between brain tissue and non-brain tissue from bulk RNA-seq studies. Furthermore, we observe that eQTL effect size agreement was highest for cell types with similar function, even when comparing brain to blood cells. This suggests that that bulk analyses substantially overestimate eQTL agreement, likely due to tissue-level averaging of cellular regulatory effects. Through colocalization, we prioritized 662 genes for 11 brain-related traits and prioritized a single cell type in 68% of genes. Our findings demonstrate that eQTL effects are far more cell-type-specific than previously recognized, underscoring the need to expand single-cell eQTL studies across diverse tissues and cell types to fully capture the regulatory architecture of genetic variants.
Identifiers
PMID41394650
PMCPMC12697720
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390